Marstacimab

CAS No. 1985638-39-8

Marstacimab( —— )

Catalog No. M37307 CAS No. 1985638-39-8

Marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody, is utilized in hemophilia research .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Marstacimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody, is utilized in hemophilia research .
  • Description
    Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia.
  • In Vitro
    ——
  • In Vivo
    Animal Model:Acute bleeding hemophilia A mouse modelsDosage:0.5 mg/kg Administration:Intravenous injection, 0.5 mg/kg, once, before tail clip Result:Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1985638-39-8
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25(5):797-806.?
molnova catalog
related products
  • 8-Phenyl-2,6-dibromo...

    8-Phenyl-2,6-dibromo-1,3,5,7-tetramethyl BODIPY can be used in photodynamic therapy.

  • Rhynchophylline

    Rhynchophylline can protect against ischemic damage, probably via regulating the Akt/mTOR pathway.

  • RET-IN-1

    RET-IN-1 is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 552.